ARYx Therapeutics Inc
OTC:ARYX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Florida Canyon Gold Inc
XTSX:FCGV
|
CA |
|
N
|
Naysaa Securities Ltd
BSE:538668
|
IN |
|
Comp SA
F:Q3W
|
PL |
|
Australian Oil Company Ltd
ASX:AOK
|
AU |
|
M
|
Modine Manufacturing Co
F:MMF
|
US |
|
DFDS AS
LSE:0RB3
|
DK |
|
B
|
Brunello Cucinelli SpA
LSE:0Q7S
|
IT |
|
Longfor Group Holdings Ltd
F:RLF0
|
CN |
ARYx Therapeutics Inc
Cost of Revenue
ARYx Therapeutics Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ARYx Therapeutics Inc
OTC:ARYX
|
Cost of Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cost of Revenue
-$30.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cost of Revenue
-$84.5m
|
CAGR 3-Years
80%
|
CAGR 5-Years
62%
|
CAGR 10-Years
32%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cost of Revenue
-$15.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cost of Revenue
-$14.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cost of Revenue
-$12.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-9%
|
|
ARYx Therapeutics Inc
Glance View
ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. The company is headquartered in Fremont, California and currently employs 56 full-time employees. The company went IPO on 2007-11-08. The firm is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. The company is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
See Also
What is ARYx Therapeutics Inc's Cost of Revenue?
Cost of Revenue
0
USD
Based on the financial report for Dec 31, 2009, ARYx Therapeutics Inc's Cost of Revenue amounts to 0 USD.
